Loading lessons…
Peptide learning paths
Learn peptides step by step
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
190lessons
8paths
0day streak
0%explored
Start your first lesson
Choose a learning path below or search the library. Progress saves in your browser.
Learning paths
Pick a track — progress rings update as you complete lessons.
Guided curriculum
Policy & compliance context (advanced)
Regulatory landscape changes fast. These modules help experienced learners interpret FDA actions, compounding rules, and supplier risk.
Who it's for: Advanced learners tracking sourcing legality and compounding pharmacy shifts.
Unit 1
Module 1 — FDA & compounding
Track reclassifications, advisory panels, and compounded peptide access.
You'll be able to
- ✓Read FDA peptide bulletins in context
- ✓Understand Category 1/2/3 framing
- ✓Anticipate supply-chain impacts
Unit 2
Module 2 — Enforcement & warnings
Warning letters, RUO marketing, and international alerts.
You'll be able to
- ✓Decode research-use-only enforcement
- ✓Cross-reference international warnings
- ✓Update personal risk checklist
7 lessons in Regulation & Policy
9mPolicyAdvanced
FDA Reclassifies 12 Peptides: What April 2026's Policy Shift Means for Biohackers
The FDA's April 15, 2026 reclassification of 12 research peptides marks the most significant regulatory shift in the space since the 2023 compounding crackdown. Here's a breakdown of the affected compounds, the new compliance landscape, and how to think about your protocol going forward.
10mPolicyAdvanced
FDA Peptide Reclassification 2026: BPC-157, GHK-Cu, and MOTS-C Return to Legal Compounding
After years of regulatory uncertainty, BPC-157, GHK-Cu, and MOTS-C are returning to legal compounding access in 2026. Here's what the FDA reclassification means for peptide researchers.
9mPolicyAdvanced
FDA's Regulatory Shift on Compounded Peptides: What the 2026 Policy Signals Mean for You
A potential FDA regulatory shift on 14 compounded peptides — including BPC-157 and TB-500 — could reshape who gets access to peptide therapy and how. Here's what the current signals actually mean.
10mPolicyAdvanced
FDA Schedules July 2026 Advisory Panel to Reclassify 12 Peptides — What It Means for BPC-157, MOTS-C, and GHK-Cu
An FDA advisory panel scheduled for July 2026 could reshape access to 12 peptides — including BPC-157, MOTS-C, and GHK-Cu. Here's what's on the table, what reclassification would mean in practice, and how to prepare for either outcome.
8mPolicyAdvanced
FDA Removes 12 Peptides from Category 2 Restrictions: What Changed in April 2026
The FDA's April 2026 announcement removed 12 peptides from Category 2 restrictions — the biggest regulatory shift in years. BPC-157, TB-500, MOTS-C, GHK-Cu, and Semax are among those affected. Here's what it actually means for your access.
9mPolicyAdvanced
Oral GLP-1s Are Here: What the Foundayo FDA Approval Means for the Peptide Community
For years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
9mPolicyAdvanced
BPC-157 and the 2026 Regulatory Shift: What the HHS Category 1 Push Means for Peptide Access
After years of regulatory limbo, BPC-157 is at the center of a major policy battle. The RFK Jr.-led HHS push to reclassify it as Category 1 could restore legal compounding access—or the FDA could dig in. Here's where things stand.
Also available at /blog for legacy links.